Close Menu

NEW YORK – Twist Bioscience said Wednesday after the close of the market that it has priced an underwritten public offering of approximately 4.6 million shares of common stock at $28 per share.

The San Francisco-based synthetic DNA producer expects gross proceeds of about $130 million from the offering, above its previous expectation of $100 million. It will use the funds invest in R&D, scale commercial operations, and expand production capacity.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.